Related references
Note: Only part of the references are listed.Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy
Julian Panes et al.
JOURNAL OF CROHNS & COLITIS (2019)
Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study
Antoine Meyer et al.
ANNALS OF INTERNAL MEDICINE (2019)
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Tomoo Nakagawa et al.
INTESTINAL RESEARCH (2019)
Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis
Catalin Codreanu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Marte L. Hoivik et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
Raguprakash Ratnakumaran et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
Maria Fernanda Guerra Veloz et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2018)
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
Viktoria Bergqvist et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
Maurizio Benucci et al.
IMMUNOLOGIC RESEARCH (2017)
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort
Anita Balint et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort
Lorant Gonczi et al.
INFLAMMATORY BOWEL DISEASES (2017)
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2017)
Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials
Zheng Zhang et al.
BMJ OPEN (2017)
Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months
F. Argulles-Arias et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
Shomron Ben-Horin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
Elena Nikiphorou et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
Sang Hyoung Park et al.
Expert Review of Gastroenterology & Hepatology (2015)
Risk and Management of Intra-Abdominal Abscess in Crohn's Disease Treated with Infliximab
Kazuaki Yoneno et al.
DIGESTION (2014)
Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a Canadian Multicenter Prospective Observational Registry
Carter Thorne et al.
ARTHRITIS CARE & RESEARCH (2014)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Anna Rita Giardina et al.
RHEUMATOLOGY INTERNATIONAL (2010)
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
Isabelle Delabaye et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
Bert Vander Cruyssen et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Maintenance of infliximab treatment in ankylosing spondylitis
Maxime Breban et al.
ARTHRITIS AND RHEUMATISM (2008)
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
R Westhovens et al.
ARTHRITIS AND RHEUMATISM (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT)
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2005)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial
J Braun et al.
LANCET (2002)
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy
F Van den Bosch et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
